



**European
Society of
Hypertension**

ESH Council Meeting

ZOOM MEETING

FEBRUARY 6, 2021

9:00 am CET

Some housekeeping remarks for our meeting

- We would like to record the meeting. Does everyone agree?
- Please mute your microphones when listening.
- Coffee Break will be from 10:30 – 10:45 am
- Finish at 12:30 pm

1. PRESIDENT'S WELCOME

(R. Kreutz)

Apologies:

- Jorge Polonia
- Bojan Jelakovic

1. PRESIDENT'S WELCOME

(R. Kreutz)

Message to Renata Cifkova

Please turn on your camera/video and we will do a screenshot and send it to her after the meeting.

In memoriam: Jiří Widimský Sr.

(R. Kreutz)

BLOOD PRESSURE
<https://doi.org/10.1080/08037051.2020.1859212>



OBITUARY



In memoriam: Jiří Widimský Sr. 1925–2020



The sad news came to us of the passing of Jiří Widimský Sr. on November 11, 2020 at the age of 95 years. This could have been expected due to the gradual deterioration of his condition in the last few years.

Professor Jiří Widimský, M.D., D.Sc., FESC, FAHA was born on March 31, 1925 in Pilsen, Czechoslovakia, where he was raised and completed his secondary educa-

experience was his 13 month fellowship (1961–1962) sponsored by the Swedish Society for Cardiology and Lung Diseases, working in the Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg, Sweden under the mentorship of Professor Lars Werkö. During that period, he published extensively and returned several times to the Department of Clinical Physiology, at Sahlgrenska; each time for a period of 3–4 months (1967, 1968, and 1969).

Widimský became an Associate Professor of Internal Medicine at Charles University in Prague in 1968 with the habilitation thesis: 'Acute pulmonary hypertension – cardiopulmonary function during unilateral pulmonary artery occlusion' [5]. He became a Doctor of Sciences (D.Sc.) in 1969 with the monograph 'Pulmonary hypertension', published in Germany: 'Pulmonale Hypertonie', G. Thieme Verlag, Stuttgart – New York [6]. Widimský became a full Professor of Internal Medicine at Charles University in Prague in 1978.

In the years 1970–1983, he was Head of the

2. MINUTES FROM ESH SCIENTIFIC COUNCIL ZOOM MEETING, November 7, 2020

(A. Januszewicz)

The meeting minutes of the last Council Meeting have been sent to all of you for approval. There has been no objection.

3. TREASURER'S REPORT

(prepared by J. Polonia and R. Schildknecht)

3a. ESH Financial Report (provisional, not audited yet)


(A. Januszewicz)

ESH Income & Expenditures as per 31.12.2020

(provisional, not audited)

Please note: all figures are shown in Swiss Francs (1 EUR = 1.08 CHF; 1 CHF = 0.93 EUR) ←

A couple of bookings are provisional and will slightly change until the Annual Meeting.



	31.12.2020 (CHF)		31.12.2019 (CHF)	
Net assets at beginning of period	1'813'266		1'798'344	
Net assets at end of period	1'849'171		1'813'266	
Profit / Loss	35'905	10.5%	14'923	1.1%
TOTAL INCOME	341'609	100.0%	1'386'355	100.0%
TOTAL EXPENSES	-305'704	-89.5%	-1'142'213	-82.4%
TOTAL EXPENDITURES	-305'704	-89.5%	-1'371'433	-98.9%


ESH Income as per 31.12.2020 (provisional, not audited)

	31.12.2020 (CHF)		31.12.2019 (CHF)	
Net assets at beginning of period	1'813'266		1'798'344	
Net assets at end of period	1'849'171		1'813'266	
INCOME				
Meeting income				
Meeting Milan	0	0.0%	997'629	72.0%
Meeting Athens	138'917	40.7%	102'483	7.4%
General Meeting income	44'739	13.1%	50'002	3.6%
Total Meeting Income	183'656	53.8%	1'150'114.20	0.0%
Subscriptions (2020 incl. Journal Fee)	41'018	12.0%	284	0.0%
Other income				
Royalties received	110'000	32.2%	122'427	8.8%
Donations	6'871	2.0%	107'538	7.8%
Endorsement for awards	0	0.0%	5'739	0.4%
Dividend/Interest Securities	63	0.0%	254	0.0%
Total Other Income	116'935	34.2%	235'957	17.0%
TOTAL INCOME	341'609	100%	1'386'355	100%

ESH Expenditures as per 31.12.2020 (provisional, not audited)

	31.12.2020 (CHF)		31.12.2019 (CHF)	
Net assets at beginning of period	1'813'266		1'798'344	
Net assets at end of period	1'849'171		1'813'266	
EXPENDITURES				
<i>Allowances to the FESH</i>	0	0.0%	-229'220	-16.5%
Meeting Expenses				
Meeting Milan	0	0.0%	-792'211	-57.1%
Meeting Athens	-102'850	-30.1%	-103'257	-7.4%
General Meeting costs	-45'961	-13.5%	-60'785	-4.4%
Total Meeting Expenses	-148'811	-43.6%	-956'253	-69.0%
Expenses for other society activities				
Subscriptions for Journal of Hypertension	-21'968	-6.4%	0	0.0%
Awards granted	0	0.0%	-5'526	-0.4%
Website expenses	-19'505	-5.7%	-40'763	-2.9%
Donations	0	0.0%	-4'359	-0.3%
Other expenses	-6'750	-2.0%	-30'416	-2.2%
Total expenses for other society activities	-48'223	-14.1%	-81'063	-5.8%
Other expenses				
Administration costs	-25'991	-7.6%	-22'550	-1.6%
Legal and professional fees	-49'116	-14.4%	-22'838	-1.6%
Bank charges	-7'949	-2.3%	-6'846	-0.5%
Gain/loss on securities	-3'098	-0.9%	-16'386	-1.2%
Gain/loss on Forex	-20'988	-6.1%	-28'677	-2.1%
Tax payments	-1'528	-0.4%	-7'600	-0.5%
Total other expenses	-108'670	-31.8%	-104'897	-7.6%
Total Expenses	-305'704	-89.5%	-1'142'213	-82.4%
TOTAL EXPENDITURES	-305'704	-89.5%	-1'371'433	-98.9%

X 1000 CHF



3b. FESH Financial Report (provisional, not audited)

(M. Burnier)

3b. FESH Financial Report (provisional, not audited)

(M. Burnier)

	31.12.2020 (CHF)			31.12.2019 (CHF)	
Net assets at beginning of period	550'741			476'913	
Net assets at end of period	554'875			550'741	
Profit / Loss	4'135	12.6%		73'827	28.2%

TOTAL INCOME	32'808	100.0%		261'815	100.0%
TOTAL EXPENDITURES	-28'673	-87.4%		-187'988	-71.8%

FESH Income as per 31.12.2020 (provisional, not audited)

	31.12.2020 (CHF)			31.12.2019 (CHF)	
Net assets at beginning of period	550'741			476'913	
Net assets at end of period	554'875			550'741	

INCOME					
<i>Allowances from the ESH</i>	0	0.0%		229'220	87.6%
Contribution to Summer School	0	0.0%		27'553	10.5%
Subscriptions of organisations	32'577	99.3%		2'219	0.8%

Other income					
Dividend/Interest Securities	231	0.7%		895	0.3%
Gain/loss on securities	0	0.0%		1'929	0.7%
Total other income	231	0.7%		2'824	1.1%

TOTAL INCOME	32'808	100%		261'815	100%
---------------------	---------------	-------------	--	----------------	-------------

FESH Expenditures as per 31.12.2020 (provisional, not audited)

	31.12.2020 (CHF)			31.12.2019 (CHF)	
Net assets at beginning of period	550'741			476'913	
Net assets at end of period	554'875			550'741	
EXPENDITURES					
Expenses for Foundation activities					
Summer School: Administration	0	0.0%		-140'339	-53.6%
Summer School: Travel	0	0.0%		-814	-0.3%
Total Summer School Expenses	0	0.0%		-141'153	-53.9%
Educational Meeting: Accomodation	0	0.0%		-5'030	-1.9%
Total expenses for FESH activities	0			-146'183	-55.8%
Other expenses					
Administration costs	-15'304	-46.6%		-15'607	-6.0%
Legal and professional fees	0	0.0%		-1'000	-0.4%
Bank charges	-2'667	-8.1%		-2'073	-0.8%
Gain/loss on securities	-814	-2.5%		0	0.0%
Gain/loss on Forex	-9'887	-30.1%		-23'126	-8.8%
Total other expenses	-28'673	-87.4%		-41'806	-16.0%
TOTAL EXPENDITURES	-28'673	-87.4%		-187'988	-71.8%

4. ESH BUSINESS MATTERS

- a. ESH Program Coordinator (R. Kreutz)
- b. ESH Social Media Activities (M. Elgner)
- c. ESH Membership (R. Kreutz, R. Lynch)
- d. ESH Office Bearers (K. Tsioufis)

4a. ESH Program Coordinator


(R. Kreutz)

Mandy Elgner

Email: eshcoordinator@eshonline.org

Phone: +49 157 39070622

Office hours: 9:00 am to 2:30 pm (flexible on demand)



4b. ESH Social Media Activities

(M. Elgner)

European Society of Hypertension @ESHypertension · Dec 31, 2020

Just published our #COVID19 ESH Task Force Review bit.ly/2Mhcp4I
We sincerely wish that the upcoming vaccinations against SARS-CoV-2 will help us soon to improve the situation in our countries and world-wide!
[@ESH_Annual](#) [@ISHBP](#) [#hypertension2021](#) [@KreutzReinhold](#)

Anna Dominiczak and Prof Alta Schutte

2 5 9

European Society of Hypertension @ESHypertension · Jan 15

ESH promotes COVID-19 vaccination.
ESH Secretary Professor Andrzej Januszewicz being vaccinated in Warsaw, Poland

[@KreutzReinhold](#) [@ESH_Annual](#) [@ISHBP](#) [@BIHSoc_Events](#) [@UofGVPAnna](#) [@alta_schutte](#) [#hypertension2021](#) [#WHS](#)

1 5 13



European Society of Hypertension @ESHypertension · Jan 25

Happy to announce our new #eshonline educational program webinar at player.vimeo.com/video/465712601 feel free to share with your colleagues and network

@KreutzReinhold @ESH_Annual @ISHBP @BIHSoc_Events @UofGRegiusAnna @alta_schutte #hypertension2021

MANAGEMENT OF HYPERTENSION DURING THE COVID-19 PANDEMIC AND BEYOND Part. 2

Moderator: A. Januszewicz (Warsaw, POLAND)

1. Comparison between 2018 European and 2020 ISH global guidelines for the management of hypertension
R. Kreutz (Berlin, GERMANY)
2. Management of drug treatment and adherence in clinical practice
M. Burnier (Lausanne, SWITZERLAND)
3. Perspectives for interventional treatment in hypertension
K. Tsioufis (Athens, GREECE)

SUPPORTED BY UNRESTRICTED EDUCATIONAL GRANT OF
TERMEDIA PUBLISHING HOUSE

8 16



Abdelsalam Saad, MD, MSc hat dich in einem Foto markiert

Abdelsalam Saad, MD, MSc @BenSaad · 29. Jan.

Management of #Hypertension During The #COVID19 Pandemic and Beyond

✓ Great webinar from the European Society of Hypertension.
@ESHypertension @KreutzReinhold

player.vimeo.com/video/465712601

#ESH #ESC #cardiotwitter #BP #cvPrev @AnastasiaSMihai
@PeroneFrancesco @AndreasGevaert

The slides contain the following information:

- Slide 1: How to measure blood pressure ESSENTIAL**
 - BP Classification and Definition of hypertension is based on office BP
 - Diagram showing a person sitting at a desk with a blood pressure cuff on their arm.
- Slide 2: European vs. ISH Guidelines**

	ESC/ESH 2018	ISH 2020
BP Thresholds for BP Screening	140/90 mmHg	130/80 mmHg
BP Thresholds for BP Treatment	140/90 mmHg	130/80 mmHg
- Slide 3: Core drug-treatment strategy for uncomplicated hypertension**
 - First-line drugs: ACE inhibitors, ARBs, CCBs, Thiazide-like diuretics, Beta-blockers
 - Second-line drugs: ACE inhibitors, ARBs, CCBs, Thiazide-like diuretics, Beta-blockers
- Slide 4: European vs. ISH Guidelines**

	ESC/ESH 2018	ISH 2020
First-line drug treatment	ACE inhibitors, ARBs, CCBs, Thiazide-like diuretics, Beta-blockers	ACE inhibitors, ARBs, CCBs, Thiazide-like diuretics, Beta-blockers
Second-line drug treatment	ACE inhibitors, ARBs, CCBs, Thiazide-like diuretics, Beta-blockers	ACE inhibitors, ARBs, CCBs, Thiazide-like diuretics, Beta-blockers

Du und 3 weitere Personen



European Society of Hypertension @ESHypertension · 25. Jan.

Happy to announce our new #eshonline educational program webinar at player.vimeo.com/video/465712601 feel free to share with your colleagues and network

@KreutzReinhold @ESH_Annual @ISHBP @BIHSoc_Events @UofGRegiusAnna @alta_schutte ...

3 5

Reactions to our webinar posting



European Society of Hypertension

4c. ESH Membership

(R. Kreutz, R. Lynch)

4c. ESH Membership

ESH Membership Status

- 22,698 Registered users on ESHonline.org
- 2,041 Members at 31/01/21
- 78 New Members (30/06/19 - 31/12/20) from:
 - 17 European countries
 - 23 Non-European countries

4c. ESH Membership

Number of Members at 31/01/21 = 2,041

Membership Fees Paid in 2020 = 280

→ Only 14 % of all registered members have paid their dues

Payment ESHOnline.org	ESH Members	ESH-ISH Members
	132	66

Payment through ISH	ESH-ISH Members	
	82	

4d. ESH Office Bearers

(K. Tsioufis)

5. ESH RESEARCH PROJECTS – Focus on Updates

- a. ESH Survey Tool (M. Burnier)
- b. Cost Action HyperChildNET Study (E. Lurbe)

5. ESH RESEARCH PROJECTS – Focus on Updates

- a. ESH Survey Tool (M. Burnier)
 - a 1. Pilot study on adherence

The SoGo system to perform online surveys:
The example of the ESH survey on adherence

M Burnier for the WG on pharmacotherapy and adherence

The SoGo survey system is a high quality and secure system

The system tool offers engaging survey design, multi-channel distribution, and complete analytics. The most sophisticated research platform in the industry delivers powerful insights, from segmentation to sentiment analysis.



[View all>>](#)

Trusted by the world's best teams

Survey can be done through:

- Emails
- Facebook
- Twitter...


Up to 1000 participants



- The security you need to protect your data while uncovering valuable insights




The ESH adherence survey of the WG: the pilot study



Question:


How many years have you been registered as a qualified healthcare professional?

Demographics



Question: in which medical specialty are you working ?

Your approach to adherence



Question:

On average, how long do you spend talking with patients about their use of medications?


An sub-analysis based on gender

Legend	Males						Females						Males	Females
Answer	no time at all	less than 1 minute	1 - 5 minutes	6 - 10 minutes	11 - 15 minutes	more than 15 minutes	no time at all	less than 1 minute	1 - 5 minutes	6 - 10 minutes	11 - 15 minutes	more than 15 minutes	N	
Responses	0	2	21	13	0	1	0	0	2	3	6	2	37	13
Percentage	0.0%	5.4%	56.8%	35.1%	0.0%	2.7%	0.0%	0.0%	15.4%	23.1%	46.2%	15.4%		



<div><div>Q 2 a↔</div><div>Q 3↕</div></div>		Male	Female	Total
less than 1 year	Count	0	0	0
	% within Q2(a)	0%	0%	0%
	% within Q3	--	--	--
	% of Total	0%	0%	0%
1-5 years	Count	1	1	2
	% within Q2(a)	2.63%	7.69%	3.92%
	% within Q3	50.00%	50.00%	100.00%
	% of Total	1.96%	1.96%	3.92%
6-10 years	Count	5	1	6
	% within Q2(a)	13.16%	7.69%	11.76%
	% within Q3	83.33%	16.67%	100.00%
	% of Total	9.80%	1.96%	11.76%
11-15 years	Count	2	3	5
	% within Q2(a)	5.26%	23.08%	9.80%
	% within Q3	40.00%	60.00%	100.00%
	% of Total	3.92%	5.88%	9.80%
over 15 years	Count	30	8	38
	% within Q2(a)	78.95%	61.54%	74.51%
	% within Q3	78.95%	21.05%	100.00%
	% of Total	58.82%	15.69%	74.51%


Questions on your patients: initiation of TTT



Question:

What percentage of patients THAT YOU SEE with hypertension, do you think do NOT initiate prescribed medication (that is, patients who do NOT take any of their prescribed medication)?


Questions on your patients: adherence to TTT



Question:

What percentage of patients THAT YOU SEE with hypertension, and who initiate their prescribed medication, DO take their medicines as prescribed?


Questions on your patients: 1-year persistence on TTT



Question:


What percentage of patients THAT YOU SEE with hypertension, and who initiate their prescribed medication, DO persist with their medication for 1 year?

Your beliefs on adherence



Question : Is most non-adherence unintentional ?


Your beliefs on adherence



Question:


There is not one specific intervention for improving adherence which is suitable for everyone

Use of assessment methods ?




Question: I take blood or urine samples to assess the adherence

Your use of adherence enhancing interventions: “talking to patients”




Question: I ask patients what level of involvement they would like in making decisions about their treatment

Your use of adherence enhancing interventions: “talking to patients”




Question: I encourage self- monitoring of blood pressure

Barriers to your use of adherent enhancing interventions




Question: I find it difficult identifying non-adherence in my patients

Barriers to your use of adherent enhancing interventions



Question: I lack experience in the use of adherence management practices

Questions about training and continuous education



Question: Have you had any training in medication adherence management and support during your education?

SoGo Survey: future perspectives

1. Presentation of the pilot study at the next ESH/ISH meeting online
2. Repeat the survey in Excellence Centers with multiple persons being able to answer the questionnaire
3. Open the access of the SoGo Survey to all Working Groups or any member of the Council of ESH with a good proposal.
4. Today the access is limited to 2 persons. Actually MB and one open access: proposal is to train Mandy and give her the access to fill in the questionnaires

5. ESH RESEARCH PROJECTS – Focus on Updates

b. COST Action HyperChildNET Study (E. Lurbe)



Growing
ideas
through
networks

HyperChildNET: Network for blood pressure research in children and adolescents - CA19115



Funded by the Horizon 2020 Framework Programme
of the European Union



HyperChildNET
COST Action



OVERALL GOALS AND STRUCTURE OF HYPERCHILDNET

Key data & supporters

Duration: 4-year Action

Proposers

- Number of Proposers: 36
- COST Country represented (20): Bosnia and Herzegovina, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, Italy, Lithuania, Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Switzerland, Turkey, United Kingdom
- International Partner Country (1) : United States


Initial Supporters

- European Society of Hypertension
- Working Group on Hypertension in Children and Adolescents (ESH)
- Universidad of Valencia (ES)
- Hospital General Universitario de Valencia (ES)




HyperChildNET aim

- **To establish a European sustainable and multidisciplinary network** of researchers, clinicians, early career investigators, health economists, decision-makers, patients, regulatory bodies, nutrition & pharma companies and medical devices manufacturers focusing on **acquiring a holistic understanding** of the **factors affecting high BP in children and adolescents** in order to propose and implement **corrective and preventive actions** both globally and locally.




DEVICES

RCO1. To benchmark, assess and select suitable devices for office BP monitoring in children and adolescents that fulfil the overall criteria of the universally acceptable standard (AAMI/ESH/ISO).




REFERENCE VALUES

RCO2. To define reference values for BP that can be applied all over Europe. This will be cornerstone for the definition of uniform criteria that allow a better stratification and follow-up of HTN in children. This is also the starting point for a better definition of BP categories.



IMPACT


RCO3. To define the best methodological approach for the European clinical and research community to assess hypertension-induced organ damage.



PREVENTION

RCO4. To produce **guides, publications and ICT-based tools** to **prevent high BP** in children and adolescents taking into account different confounding factors (obesity, physical activity, eating patterns, smoking, social and psychological factors, family communication skills) for a wide range of target groups (clinicians, researchers, decision-makers, patient organisations, families, media and general society representing organisations).

RCO5. To **assess the economic impact** of recommended policies and stakeholders' intervention.



DISSEMINATION

To disseminate the results of the HyperChildNet among paediatricians, family doctors, nurses, families, scientific societies and other national and international stakeholders.

Working groups

WORKING GROUPS	WG1 Blood pressure <u>devices</u>	Methodology: <ul style="list-style-type: none">• Seminars• Short-term scientific missions• Training Schools (HyperChildNET Academy)• Collaboration of local projects and research groups: data exchange, common comprehension, scientific publications, concerted strategies and action plans.• Dissemination, transference and impact
	WG2 Blood pressure <u>reference values</u>	
	WG3 <u>Impact</u> of high blood pressure in children and adolescents	
	WG4 <u>Prevention</u> of high blood pressure in children and adolescents	
	WG5 <u>Dissemination</u> and awareness	



HyperChildNET methodology

- All members of the network and the research projects will **collaborate** by creating working groups.
- In order to promote the research objectives foreseen, HyperChildNET will organise conferences, seminars, short-term scientific missions, training schools and will **produce** reports, studies, guides, strategy documents and action plans.
- For the first time, in HyperChildNET a large scale and long-term network of researchers will **result** in publication of joint protocols, guides, publications and policy proposals.

Grant Agreement Signed

- This document has been officially signed between the Grant Holder (University of Valencia) and the COST Association.
- The work plan and budget are officially approved.



Planning of the First Grant Period 2020-2021

In summary

	OCT	NOV	DEC	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT
Online MC meetings	x						x						
Online Core Group meetings			x	x			x						
Online WGs meetings				x			x						
Short Term Scientific Missions				x	x	x	x	x	x	x	x	x	x
HYBRID EVENT: Core Group meeting (face-to-face) and hybrid MC and WGs meetings and conference in Valencia												x	
Research collaboration tasks by the Working Groups	x	x	x	x	x	x	x	x	x	x	x	x	x
Website	x	x	x	x									
Visual identity, Booklets & posters (online)	x	x											

Website – www.hyperChildNET.eu




[Home](#) [HyperChildNET](#) [Networking actions](#) [Working groups](#) [Observatory](#) [Get involved](#) [Contact](#)



Network for blood pressure research in children and adolescents

The COST Action **HyperChildNET** is aimed at establishing a European sustainable and multidisciplinary network focused on acquiring a **holistic understanding of the factors affecting high BP in children** in order to propose and implement **corrective and preventive actions** both globally and locally.

[What is exactly?](#)



LIST OF PARTICIPANTS

CORE GROUP

Core Group – members



Prof Empar Lurbe

Universidad de Valencia (ES)

Chair



Prof Elke Wühl

University Hospital Heidelberg (DE)

Vice Chair



Prof Stella Stabouli

Aristotle University Thessaloniki (EL)

WG1 Leader.



Prof Giuseppe Mancia

University of Milano-Bicocca (IT)

WG2 Leader.



Prof Mieczyslaw Litwin

The Children's Memorial Health Institute (PL)

WG3 Leader.



Prof Dorota Drozd

Jagiellonian University Medical College (PL)

WG4 Leader.



Prof Jorge Polonia

Faculty of Medicine of Porto (PT)

WG5 Leader.



Dr Manish Sinha

Evelina London Childrens Hospital, UK/ King's College London (UK)



Prof Fernando Fernandez-Aranda

University Hospital of Bellvitge-IDIBELL (ES)

Science Communication Manager



Prof Giacomo Simonetti

Pediatric Institute of Southern Switzerland

ITC CG Coordinator

6. ESH ANNUAL MEETINGS

- a. 2021 ESH-ISH Joint Virtual Meeting, Glasgow (*R. Kreutz, M. Massaro*)
 - a1. ESH Awards
- b. 2022 ESH Meeting, Athens (*K. Tsioufis, M. Massaro*)
 - b1. Pre-ESH Athens 2022 Satellite Symposium
- c. 2023 ESH Meeting, Milan (*M. Massaro, G. Mancia*)

6. ESH ANNUAL MEETINGS

- a. 2021 ESH-ISH Joint Virtual Meeting, Glasgow (*R. Kreutz, M. Massaro*)
 - a1. ESH Awards



JOINT MEETING **ESH-ISH** 2021 **ON-AIR**

April 11-14, 2021
www.hypertension2021.org



European
Society of
Hypertension



International
Society of
Hypertension



FIGURES' UPDATE

REGISTRATIONS

Registered to date: **approx. 1.600**

* Faculty members not included (n. 181 pax)

ABSTRACTS

Total abstracts included in the programme: **1.347**

- Oral Communication – **238**
- Poster **1109**

SPONSORS' UPDATE

CONFIRMED AT JANUARY 2021

- | | |
|---------------|-------------|
| - ABBOTT | - OMRON |
| - ASTRAZENECA | - RECOR |
| - BAYER | - SANOFI |
| - MEDTRONIC | - SERVIER |
| - MENARINI | - SPACELABS |
| - MERCK | - VIFOR |

SPONSORS' UPDATE

SPONSORED SESSIONS: 20 total (18 confirmed at march 2020 for ESH-ISH Glasgow 2020)

- ABBOTT – 1 minisymposium
- ASTRAZENECA – 1 minisymposium
- BAYER – 1 minisymposium
- MEDTRONIC – 1 satellite symposium
- MENARINI – 3 minisymposia
- MERCK – 1 satellite symposium
- OMRON – 2 minisymposia + Academy Online
- RECOR – 2 minisymposia
- SANOFI – 1 minisymposium
- SERVIER – 2 satellite symposia + 2 minisymposia
- VIFOR – 2 minisymposia

PROGRAMME OVERVIEW

All sessions included in the programme-at-a-glance will be transmitted “live” respecting the time and (virtual) room; afterwards available in the on-demand section of the platform.

E-posters will be directly available on the on-demand section without any time schedule or restriction.

Times in the programme are indicated in CEST (Central European Summer Time).

The whole content of the Meeting will be available on-demand for 3 months after the live event, until July 15th, 2021.

The following legend will help understand the different sessions in the timetable:

	plenary & live sessions
	institutional sessions
	sponsored sessions
	satellite symposia
	ISH Sessions
	non-usable slot
	oral communications

TIMETABLE – APRIL 11

TIME	AUDITORIUM 1000 users	ROOM 1 500 users	ROOM 2 500 users	ROOM 3 250 users	ROOM 4 250 users	ROOM 5 250 users	ROOM 6 250 users
11.00 12.00	OPENING OF THE CONGRESS <i>11.20-11.40</i> <i>Lecture Prof Dzau</i>						
12.00 13.00	45 MIN Mini-symposium Supported by <i>Omron</i> ADVANCES IN TECHNOLOGY, PIONEERING NEW PRACTICES IN NOCTURNAL HYPERTENSION ASSESSMENT IN PATIENTS AT RISK	Joint Session ESH-ISH-POA EFFECTIVE PRECISION DIAGNOSIS AND THERAPIES OF HYPERTENSION FOR CLINICIANS	45 MIN Mini-symposium Supported by <i>Sanofi</i>	19th International SHR Symposium GENETICS AND DISEASE MODEL GUIDED NOVEL THERAPEUTIC TARGET DISCOVERY IN HYPERTENSION	BIHS Symposium	ESH WG on Hypertension and the Brain SUPPORTING ROUTINE ASSESSMENT OF COGNITIVE FUNCTION IN HYPERTENSIVE PATIENTS: A POSITION PAPER OF THE WG	12.30-13.30 ESH WG on Interventional Treatment of Hypertension
13.00 14.00	Satellite Symposium Supported by <i>Servier</i>	ESH WG on Vascular Structure and function DEFINING A NOVEL APPROACH FOR VALIDATION OF NEW DEVICES FOR ARTERIAL STIFFNESS MEASUREMENT	ESH WG on Obesity, Diabetes and the High Risk Patient WOMEN A HIGH RISK POPULATION: REPRODUCTION, HORMONES AND CARDIOVASCULAR RISK	ESH WG on Hypertension and cardiovascular risk assessment in subjects living in or emigrating from low resource settings COMPREHENSIVE APPROACH FOR HYPERTENSION CONTROL IN AFRICA		ESH WG on Cardiovascular Pharmacotherapy and Adherence	13.30-14.30 ESH WG on Hypertension and the Heart HYPERTENSION IS THE MOST IMPORTANT CAUSE OF HFPEF: MECHANISMS AND MANAGEMENT
14.00 15.00	Satellite Symposium Supported by <i>Medtronic</i>	ESH WG on Hypertension in Children and Adolescents HYPERTENSION IN YOUTH: NEW INSIGHTS	ESH WG on Hypertension and the Kidney ADVANCES ON DIAGNOSIS, PATHOPHYSIOLOGY AND TREATMENT OF HYPERTENSION IN PATIENTS WITH CKD	ESH WG on Endothelins and Endothelial Factors UNSOLVED ISSUES IN ENDOTHELIAL DYSFUNCTION IN ARTERIAL HYPERTENSION	ESH WG on Hypertension and Sexual Dysfunction SEXUAL DYSFUNCTION AND ANTIHYPERTENSIVE THERAPY	ISH Regional Advisory Group - Africa	
15.00 16.00	45 MIN Mini-symposium Supported by <i>Servier</i>	45 MIN Mini-symposium Supported by <i>Bayer</i> PROTECTING THE BRAIN: WHY KIDNEYS MATTER?	45 MIN Mini-symposium Supported by <i>Menarini</i> <i>Zofenopril</i>	The Balkan Symposium	Oral Communications CARDIOVASCULAR RISK FACTORS	ESH WG on Endocrine Hypertension	Oral Communications GENETICS, GENOMICS, PROTEOMICS, METABOLOMICS + LECTURE (Caufield)
16.00 17.00	45 MIN Mini-symposium Supported by <i>Menarini Olmesartan</i>	45 MIN Mini-symposium Supported by <i>Astrazeneca</i> IMPROVING CARDIORENAL OUTCOMES IN HYPERTENSION	45 MIN Mini-symposium Supported by <i>ReCor</i>		Oral Communications Late-breaker Abstracts	Oral Communications RESISTANT HYPERTENSION INTERVENTIONAL THERAPIES + LECTURE (Tsioufis)	Oral Communications EPIDEMIOLOGY OF HT AND METABOLIC DISORDERS

TIMETABLE – APRIL 12

TIME	AUDITORIUM 1000 users	ROOM 1 500 users	ROOM 2 500 users	ROOM 3 250 users	ROOM 4 250 users	ROOM 5 250 users	ROOM 6 250 users
11.00 12.00	Topical Workshop on Hot Issues HYPERTENSION IN PREGNANCY	The Iberican Session THE IBERICAN STUDY: ANALYSIS OF CARDIOVASCULAR RISK IN SPAIN	ISH Hypertension Guidelines THE ISH 2020 GLOBAL HYPERTENSION PRACTICE GUIDELINES	Joint Session ESH-ISH-KSH IMPORTANCE OF AMBULATORY BLOOD PRESSURE MONITORING IN CARDIOVASCULAR PREVENTION	Oral Communications EXPERIMENTAL HT AND PHARMACOLOGY	Oral Communications MICROCIRCULATION / SMALL VESSELS + LECTURE (Steckelings)	Workshop HYPERTROPHY OF THE HEART – THE KEY/CENTRAL HMOD REVISITED
12.00 13.00	Plenary Session Presentation of ESH Awards						
13.00 14.00	Satellite Symposium Supported by <i>Servier</i>	Teaching Seminar SESSION 1	Oral Communications CEREBROVASCULAR DISEASE STROKE AND COGNITIVE DYSFUNCTION + LECTURE (Iadecola)	Oral Communications DIABETES		Oral Communications PREGNANCY	ISH Regional Advisory Group - South and Central Asia
14.00 15.00	45 MIN Mini-symposium Supported by <i>Omron</i>	45 MIN Mini-symposium Supported by <i>Vifor</i>	45 MIN Mini-symposium Supported by <i>Abbott</i>	Joint Session ESH-ISH-ESC	Workshop CERTIFICATE COURSE IN MANAGEMENT OF HYPERTENSION : A NOVEL CAPACITY BUILDING INITIATIVE	GLOBAL CVD + LECTURE (Reddy)	ISH Austin Doyle Award Session
15.00 16.00	45 MIN Mini-symposium Supported by <i>Servier</i>	Oral Communications KIDNEY	45 MIN Mini-symposium Supported by <i>ReCor</i>	How-to Session FIBROMUSCULAR DYSPLASIA (FMD), A MULTIFACETED SYSTEMIC ARTERIAL DISEASE	Topical Workshop HYPERTENSION IN CHILDREN AND ADOLESCENTS: FROM PRIMORDIAL PREVENTION TO ADVANCED ASSESSMENT	Oral Communications COVID-19 AND HYPERTENSION	ISH New Investigator Committee Award Session
16.00 17.00	<i>Omron</i> Academy online	45 MIN Mini-symposium Supported by Menarini Nebivolol	Oral Communications TREATMENT ADHERENCE (Lectures Mancia and Oparil)	Oral Communications BIOMARKERS	Joint Session ESH-ISH-BIHS (Young investigator Symposium) DEVELOPING COLLABORATIONS TO FURTHER YOUR CAREER	Oral Communications MULTI-MORBIDITY AND CO-MORBIDITIES + LECTURE (Sarafidis)	Workshop IMMUNITY AND INFLAMMATION IN HYPERTENSION – FROM BASIC MECHANISMS TO CLINICAL TRANSLATION

TIMETABLE - APRIL 13

TIME	AUDITORIUM 1000 users	ROOM 1 500 users	ROOM 2 500 users	ROOM 3 250 users	ROOM 4 250 users	ROOM 5 250 users	ROOM 6 250 users
11.00 12.00	Topical Workshop on Hot Issues TREATMENT ADHERENCE AND INERTIA IN HYPERTENSION	Joint Session ESH-ISH-CHL OUT-OF-OFFICE BLOOD PRESSURE MEASUREMENT	Joint Session ESH-ISH- Indian Society of HY FEATURES OF HYPERTENSION AND CARDIOVASCULAR DISEASE IN INDIA	Workshop 24 HOUR BP PROFILE AND SYMPATHETIC DRIVE	Workshop GLOBAL TRAINING PROGRAMS TO IMPROVE HYPERTENSION CARE: FUNDAMENTAL BUT UNDERAPPRECIATED ASPECT	Workshop European Council for Cardiovascular Research (ECCR) – High blood pressure research council of Australia (HBPRCA) SOME NEW CONCEPTS IN HYPERTENSION	Oral Communications INFLAMMATION AND IMMUNITY
12.00 13.00	Plenary Session Presentation of ISH Awards						
13.00 14.00	Satellite Symposium <i>Supported by Merck</i>	Teaching Seminar SESSION 2	Oral Communications THERAPEUTICS AND CLINICAL TRIALS + LECTURE (McMurray)	Oral Communications LARGE ARTERIES		Oral Communications CHILDREN AND ADOLESCENTS	30min ESH General Assembly + 30min ESH Welcome of new Members
14.00 15.00	MAY MEASUREMENT MONTH	Oral Communications ENDOCRINE HYPERTENSION	Joint Session ESH-ISH-LASH ADIPOSY, MUSCULAR STRENGTH AND CARDIOMETABOLIC DISEASE: FROM FOETAL PROGRAMMING TO SARCOPENIA IN THE ELDERLY	Workshop RENOVASCULAR HYPERTENSION	Portuguese Session HTN AND CARDIOVASCULAR RISK IN PORTUGUESE SPEAKING COUNTRIES	Workshop TECHNOLOGICAL ADVANCES FROM LARGE TO SMALL ARTERIES AND USEFULNESS IN HYPERTENSION	45 MIN DEBATE ACCURATE MEASUREMENT OF BLOOD PRESSURE: DO WE NEED TO DO BETTER?
15.00 16.00	ESH BPM Teaching Course (No Title)	Oral Communications RENIN ANGIOTENSIN ALDOSTERONE SYSTEM	Clinical Cases CLINICAL-PATHOLOGICAL CONFERENCE (CPC)	Topical Workshop THE GLOBAL BATTLE AGAINST HYPERTENSION - THE LANCET COMMISSION ON HYPERTENSION AND CDC	First Scientific International Society of Hypertension Middle East North Africa, Regional Advisory Group Program	Meet-the-Expert LOST IN TRANSLATION – IS 'FROM BENCH TO BEDSIDE' THE HOLY GRAIL?	Oral Communications AGEING
16.00 17.00		45 MIN Mini-symposium <i>Supported by Vifor</i>	ISH Americas Regional Advisory Group Session Hypertension in the Americas	Oral Communications BIG DATA + LECTURE (Arnett)	Oral Communications OBESITY AND METABOLIC SYNDROME + LECTURE (Joe)	Oral Communications BLOOD PRESSURE VARIABILITY	Workshop HYPERTENSIVE EMERGENCIES MANAGEMENT

TIMETABLE – APRIL 14

TIME	AUDITORIUM 1000 users	ROOM 1 500 users	ROOM 2 500 users	ROOM 3 500 users	ROOM 4 500 users	ROOM 5 500 users
11.00 12.00	Topical Workshop on hot Issues ARE ELECTRONIC CIGARETTES A FAVOURABLE ALTERNATIVE TO SMOKING IN CARDIOVASCULAR PATIENTS?	WHL IMPLEMENTING THE CALL TO ACTION FOR GLOBAL HYPERTENSION CONTROL	Workshop ENVIRONMENTAL POLLUTION AND HYPERTENSION	Workshop CVD DETECTION, PREVENTION AND CONTROL IN LOW- AND MIDDLE-INCOME COUNTRIES: FIELD EPIDEMIOLOGY TRAINING PROGRAM (FETP) STORIES FROM THE FIELD	Oral Communications LIFESTYLE CHANGES / LIPIDS / SALT + LECTURE (Collins)	Live session on basics of renal ultrasound in hypertensive patients
12.00 13.00	Teaching Seminar SESSION 3	How to Session WOMEN IN HYPERTENSION RESEARCH - MAXIMISING OPPORTUNITIES AND REACHING CAREER GOALS	Workshop NUTRITION, MICROBIOMA AND CARDIOVASCULAR RISK	Meet-the-Expert HOW TO DO A GOOD META-ANALYSIS OF OUTCOME RANDOMIZED TRIALS IN HYPERTENSION?	Oral Communications ATRIAL FIBRILLATION	
13.00 14.00	Topical Workshop HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) AND HYPERTENSIVE HEART DISEASE – TWINS OR JUST DISTANT RELATIVES?	Oral Communications GLOBAL BURDEN OF HYPERTENSION + LECTURE (Smith)	Oral Communications BLOOD PRESSURE MEASUREMENT	Oral Communications PRIMARY ALDOSTERONISM	Workshop TREATING HYPERTENSIVE PATIENTS WITH DIFFERENT NEUROLOGIC CONDITIONS AND AGE GROUPS: TARGETS	
14.00 15.00	Closing Plenary Session 14.00-14.40 Debate: HYPERTENSION: IS IT ALL ABOUT ALDOSTERONE? 14.40-15.00 launch ESH 2022, launch ISH 2022, President's farewell					

NATIONAL SOCIETIES

Both ESH and ISH, have developed their Affiliation and Association programmes to establish effective liaisons between them and National and International Societies of Hypertension.

Below you can find the list of the societies that are helping to promote the ESH-ISH 2021 ON-AIR Joint Meeting.
This list is constantly updated.

Austrian Society of Hypertension
Argentina Arterial Hypertension Society
Belgian Hypertension Committee
British & Irish Hypertension Society (BIHS)
Croatian Society of Hypertension
Czech Hypertension Society
Danish Hypertension Society
French Society of Hypertension
German Hypertension League
Hellenic Society of Hypertension
Hungarian Society of Hypertension


Israeli Society of Hypertension
Italian Society of Hypertension
Japanese Society of Hypertension
Norwegian Hypertension Association
Polish Society of Hypertension
Portuguese Society of Hypertension
Romanian Society of Hypertension
Serbian Society of Hypertension
Slovenian Hypertension Society
Swedish Society of Hypertension, Stroke and Vascular Medicine
Swiss Society of Hypertension

**In the light of the partnership with these societies,
we propose to offer them a free booth in the platform with a special discounted rate for customization.**

GLASGOW

As Glasgow was initially supposed to be the Joint Meeting 's hosting city and considering the good relation built between the local institutions and the Societies, it would be nice to maintain a link with the city.

Whilst our delegates will not have the opportunity to visit the city in person, adding some Glasgow character to our Meeting, like virtual tours and other useful contents to give a sense of the city, could be a great way to support local businesses and encourage virtual attendees to visit the city in the future!



DIGITAL PROMOTION

We keep on working on our daily promotional activity and followers are constantly increasing in both social media:

- Twitter: 974 (+ 5% compared to March 2020)



@ESH_Annual

- Facebook: 627 (+ 5% compared to March 2020)



@ESHAnnualMeetings

Help us to promote!

#hypertension2021

See you ON-AIR!



6 a1. ESH AWARDS 2021



Dear ESH Colleagues,

The Awards Committee of the European Society of Hypertension (ESH) invites nominations from members of the ESH for each of the awards listed below:

Björn Folkow Award and Lecture

This is awarded to a person or persons who have carried out original research in physiology that has contributed to the understanding of pathogenesis of hypertension.

Alberto Zanchetti Life Achievement Award

The award is conferred to a scientist with a life-long, high-quality career in scientific research in the field of hypertension.

ESH Honorary Membership

Honorary membership is granted to a scientist who has made extraordinary contributions to research in hypertension or who has given exceptionally important support to the activities of the Society.

Peter A. van Zwieten Award

This award is dedicated to the late Prof. Peter A. van Zwieten in recognition of his exceptionally important support to the activities of the Society. This award is conferred to a scientist with achievements in the field of cardiovascular pharmacology.

The letter of nomination for each award should address the evaluation criteria for the award, including significant contributions and achievements made by the nominee. The letter should confirm the nominee has agreed to be nominated and is a member of the ESH and includes the nominee's Curriculum Vitae.

ESH Awards Committee

R. Kreutz

E. Lurbe

C. Tsioufis

A. Januszewicz

G. Mancia



6 a1. ESH AWARDS 2021

Servier Research Grant in Hypertension



**Next deadline
for applications
February 28, 2021**

The Servier Research Grant in Hypertension in the amount of **€ 30 000** is awarded **every 2 years** for a research proposal in the field of hypertension.

A short research proposal (max. 10 pages with the following structure: title, background, working plan incl. hypotheses and aims, material, methods, budget and references) should be submitted latest by February 28, 2021.

ESH Awards Committee

R. Kreutz
E. Lurbe
C. Tsioufis
A. Januszewicz
G. Mancia

Talal Zein Award


The Talal Zein Foundation offers the award to the 3 best oral abstracts and the 3 best posters presented at the annual meeting. The winners will be selected from the final program.

6. ESH ANNUAL MEETINGS

b. 2022 ESH Meeting, Athens (*K. Tsioufis*)



32nd European Meeting



on Hypertension and Cardiovascular Protection

June 17-22, 2022
Athens, Greece

Megaron Athens International
Conference Centre (MAICC)



save • the • date



6. ESH ANNUAL MEETINGS

b1. Pre-ESH Athens 2022 Satellite Symposium

Pre-ESH Athens 2022 Satellite Symposium
A roadmap to the new
European Hypertension
Guidelines

MILAN - October 29-31, 2021



WHY

Due to the global situation related to COVID-19 and the resulted postponement of the ESH-ISH Joint Meeting, the activity of the European Society during the last months has been reduced.

For this reason, during this prolonged time without official European congress, the ESH developed a **new hybrid project** in the form of a Pre-ESH 2022 Meeting, dedicated to guidelines issues, selected among those most widely debated or on which new evidence has been made available.

The Meeting, titled “**A ROADMAP TO THE NEW EUROPEAN HYPERTENSION GUIDELINES**” will have the purpose to prepare the stage for recommendations (novelties; changes; confirmations) to be possibly implemented in the future guidelines.

FORMAT

The Meeting will last one day and a half and involve a limited number of top international experts, largely but not exclusively from Europe.

The format of the event is hybrid, to ensure the possibility of participating for Faculty members in person in Milan and in virtual mode for delegates.

The scientific programme will be selected and supervised by an *ad-hoc* ESH generated scientific committee.

All topics will be discussed in a plenary mode and each one will be addressed by a position paper, a short presentation by a discussant and a general discussion.

TOPICS

- Classification of BP. Should the US guidelines gain ground?
- Which cardiovascular risk factors should be measured?
- Which approach to total CV risk quantification?
- Hypertension-related organ damage. Is its search necessary? How much in depth?
- Which “office” BP should be used? Attended? Unattended? Others?
- Out-of-office BP: routine, large or ad-hoc use?
- Threshold office BP for drug treatment.
- Target office BP for treatment.
- The problem of the threshold-target BP gap in some guidelines?
- How do we determine out-of-office BP targets?
- Should salt restriction be drastic or moderate?
- Nonpharmacological treatment: can new approaches be considered?
- Diuretics – Thiazide vs thiazide-like choice.
- RAS blockers: ACE inhibitors or Angiotensin receptor blockers?
- Single pill combination. Optional use or a must?
- Dual combination treatment. How to differentiate use of RAS blockers with CCB vs diuretics?
- Triple therapy: treatment backup or initial step?
- White coat and masked hypertension. Can we be less vague about treatment options?
- Diabetes - Is antihypertensive treatment superimposable to that of non-diabetic patients?
- The case of the coronary hypertensive patient.
- Heart failure with reduced or preserved EF in hypertensive patient. Any novelty?
- Resistant hypertension – Should choice of the fourth drug be less restrictive?
- Renal denervation and other device-based treatments – Time for a re-upgrading?
- Follow-up of hypertensive patients. Are current recommendations evidence-based and agreeable?
- Adherence to treatment. An abundance of general concepts but little practical help to the practicing physician.
- Class and strength of recommendations. Time to make them simpler and easier to remember?
- Meta-analysis. Is its position as top scientific evidence justified?
- Covid-19 and hypertension . What did the collected evidence teach us and where should future studies be directed?
- Guidelines – Short or long and explanatory documents?
- Real life research data. Crucial supplementary information or low quality poorly usable data

SPONSORSHIP

We are giving the opportunity to our major sponsor to be part of this new hybrid event dedicated to the new Hypertension and Cardiovascular Protections' guidelines, where the most influential players in the field will meet.

2 different packages have been proposed as Educational Grants, which will entitle the sponsor to structure 1 webinar, to be included in the Event Programme. The faculty can be selected among the KOL already involved, present both locally or remotely.



POSSIBLE TIMETABLE – Oct. 30 (full day)

A M	Welcome message	
	08.30 – 09.15	SESSION 1
	09.15 – 10.00	SESSION 2
	10.00 – 10.45	SESSION 3
	10.45 – 11.00	<i>coffee break</i>
	11.00 – 11.45	SESSION 4
	11.45 – 12.30	SESSION 5
P M	12.30 – 13.15	SESSION 6
	13.45 – 14.45	SPONSORED WEBINARS
	15.00 – 15.45	SESSION 7
	15.45 – 16.30	SESSION 8
	16.30 – 16.45	<i>coffee break</i>
	16.45 – 17.30	SESSION 9
	17.30 – 18.15	SESSION 10
	18.45 – 19.45	SPONSORED WEBINARS

POSSIBLE TIMETABLE – Oct. 31 (half day)

A M	08.00 – 08.45	SESSION 11
	08.45 – 09.30	SESSION 12
	09.30 – 10.15	SESSION 13
	10.15 – 11.00	SESSION 14
	11.00 – 11.15	<i>coffee break</i>
	11.15 – 12.00	SESSION 15
	12.00 – 12.45	SESSION 16
	12.45 – 13.30	SESSION 17
P M	14.00 – 15.00	SPONSORED WEBINARS
	15.15 – 16.00	SESSION 18
	16.00 – 17.15	SESSION 19

6. ESH ANNUAL MEETINGS

c. ESH Meeting, Milan 2023 (*M. Massaro, G. Mancia*)

Date: June 23 – 26, 2023



Location: MiCo - Milano Convention Centre

7. ESH ACTIVITIES ON COVID-19

(A. Januszewicz)

Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19

European Society of Hypertension COVID-19 Task Force Review of Evidence

Reinhold Kreutz ^{1*}, Engi Abd El-Hady Algharably¹, Michel Azizi², Piotr Dobrowolski ³, Tomasz Guzik⁴, Andrzej Januszewicz³, Alexandre Persu ⁵, Aleksander Prejbisz ³, Thomas Günther Riemer¹, Ji-Guang Wang ⁶, and Michel Burnier ⁷

The corona-virus disease 2019 pandemic compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of Hypertension

European Society of Hypertension Corona-virus Disease 19 Task Force*

Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic

Reinhold Kreutz^{a,*}, Piotr Dobrowolski^{b,*}, Aleksander Prejbisz^b, Engi A.E-H Algharably^a, Grzegorz Bilo^{c,d}, Felix Creutzig^{e,f}, Guido Grassi^g, Vasilios Kotsis^h, Dragan Lovicⁱ, Empar Lurbe^{j,k}, Pietro A. Modesti^l, Marco Pappaccogli^{m,n}, Gianfranco Parati^{c,d}, Alexandre Persuⁿ, Jorge Polonia^o, Marek Rajzer^p, Philippe de Timary^q, Thomas Weber^r, Burkhard Weisser^s, Konstantinos Tsioufis^t, Giuseppe Mancia^{u,v}, and Andrzej Januszewicz^b, European Society of Hypertension COVID-19 Task Force Review

Cardiovascular Research (2020) 0, 1–12

Journal of Hypertension 2021, 39:190–195

J Hypertens 38:000–000



European
Society of
Hypertension

Continuation of the survey for 2nd Covid-19 wave and:

- Comparison of 2nd wave with the 1st Covid-19 wave
- Focus on secondary HT : RVHT, PA, Pheo
 - a. Number of procedures in 2019 vs 2020 vs 2021
 - b. Hospitalized patients
 - c. Biochemical tests (saline test etc)
 - d. Imaging procedures (Doppler duplex, other)
- Analysis of BP values / profile based on ABPM recordings – comparison of representative periods of 2019 vs 2020
- Analysis of trends in HT treatment : 2019 vs 2020

The corona-virus disease 2019 pandemic compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of Hypertension: European Society of Hypertension Corona-virus Disease 2019 Task Force




FIGURE 1 Summary of the effects of corona-virus disease 2019 and the associated shutdown of routine healthcare services for hypertensive patients.

2 www.jhypertension.com

Volume 38 • Number 1 • Month 2020

Journal of Hypertension 2021, 39:190–195

8. ESH AND JOURNAL OF HYPERTENSION

(R. Kreutz, G. Mancia)

Journal of Hypertension and Wolters Kluwer

Contract from 2014 signed by former ESH President Anna F. Dominiczak

THIS AFFILIATION AGREEMENT is made on 2/18/14, 2013 [the 'Execution Date']

AMONG:

[1] Wolters Kluwer Health, Inc., on behalf of its Medical Research/Lippincott Williams & Wilkins business [hereinafter called 'the Publisher'], and

[2] the International Society of Hypertension [hereinafter called 'the ISH' or a 'Society'], and

[3] the European Society of Hypertension [hereinafter called 'the ESH' or a 'Society' and, together with the ISH, the 'Societies']

According to paragraph 2.2. and based on the fact that there was no termination, the current contract is in effect until December 2021. If ESH wants to terminate the contract, this should be done before December 2020.

Journal of Hypertension and Wolters Kluwer



**European
Society of
Hypertension** www.eshonline.org

President
Prof. Reinhold Kreutz
Germany

Vice President
Prof. Empar Lurbe
Spain

Secretary
Prof. Andrzej Januszewicz
Poland

Treasurer
Prof. Jorge Polonia
Portugal

Officer at Large
Prof. Bojan Jelakovic
Croatia

Immediate Past President
Prof. Konstantinos Tsioufis
Greece

November 17, 2020

Philip J. Daly, PhD
Senior Publisher, Medical Journals
Health Learning, Research & Practice

Wolters Kluwer
Citi Building, 41st Floor
25 Canada Square
Canary Wharf
London E14 5LQ, UK

AFFILIATION AGREEMENT

Dear Phil,

I am writing to you today on behalf of the European Society of Hypertension (ESH) in relation to the current AFFILIATION AGREEMENT between Wolters Kluwer Health, Inc. (Publisher) and the International Society of Hypertension (ISH) and the ESH that was signed by the ESH in 2014.

On behalf of the ESH, I would like to inform you that in parallel of the appointment of the new Editor in Chief we now see an opportunity to reorganize the relations between the Publisher, ISH and ESH regarding the Journal of Hypertension. We aim to develop a new contract under adapted conditions. Accordingly, we do not wish to renew the current agreement from 2014 and hereby terminate it. In this respect, we look forward to the constructive discussions with the partners involved, which in our opinion should take place in a timely manner.

With kind regards,

Prof. Reinhold Kreutz
President



**European
Society of
Hypertension**

9. WORKING GROUPS

(A. Persu)

9. ESH WORKING GROUPS (*A. Persu*)

- 1. Who are WG members? Preliminary data
- 2. New WGs: next steps?

1. Working Group Analysis: preliminary data

(A. Persu, M. Elgner)

Basis:

- Information on the ESH Website → List of Working Group Members
- ESH member's list by Infomedica
(problem: some datasets are incomplete – e.g. missing date of birth)


Questions:

- Are all stated WG members also ESH members?
- What is the number of WG members ≤ 40 years of age?


The Working Group on Hypertension and the Heart does not have list of members on the website. It is therefore excluded from the following analysis.

Percentage of ESH Members amongst Working Group Members

Working Group



We only have the date of birth from the ESH members. But there are still some ESH members without their date of birth in the system.



2. New Working Groups: next steps

Updated WG list

No.	Working Group
1	HYPERTENSION IN CHILDREN AND ADOLESCENTS
2	BLOOD PRESSURE MONITORING AND CARDIOVASCULAR VARIABILITY
3	CARDIOVASCULAR PHARMACOTHERAPY AND ADHERENCE
4	ENDOCRINE HYPERTENSION
5	LARGE VESSELS
6	SMALL VESSELS
7	HYPERTENSION AND CARDIOVASCULAR RISK ASSESSMENT IN SUBJECTS LIVING IN OR EMIGRATING FROM LOW RESOURCE SETTINGS
8	HYPERTENSION AND THE KIDNEY
9	HYPERTENSION AND THE BRAIN
10	HYPERTENSION AND THE HEART
11	INTERVENTIONAL TREATMENT OF HYPERTENSION
12	OBESITY, DIABETES AND THE HIGH-RISK PATIENTS

New WGs?

New WG on non-pharmacological approaches in HTN? (J. Polonia)

New WG on HTN in the elderly? (R. Kreutz)






**European
Society of
Hypertension**

10. ESH EDUCATIONAL ACTIVITIES

- a. Eshonline platform (A. Januszewicz, R. Kreutz)
Educational Grant by SERVIER
- b. Webinar “Controversial issues of recent guidelines” (E. Agabiti Rosei)
Educational Grant by Menarini
- c. Webinar series „Educational Imaging Program in Hypertension“ in cooperation with Siemens Healthcare Poland (A. Januszewicz)
- d. Participation in meetings and cooperation with other societies
 - ESC (T. Kahan)
 - Russian Society of Hypertension (R. Kreutz)
 - Others

10. ESH EDUCATIONAL ACTIVITIES




- a. Eshonline platform (A. Januszewicz, R. Kreutz)
Educational Grant by SERVIER




**MANAGEMENT OF HYPERTENSION DURING
THE COVID-19 PANDEMIC AND BEYOND *Part. 1***

Moderator: R. Kreutz (Berlin, GERMANY)

- 1. Impact of Covid-19 on changes in lifestyle and traditional risk factors and on hypertension management**
E. Agabiti Rosei (Brescia, ITALY)
- 2. Impact of Covid-19 on changes in non-traditional and environmental factors**
P. van de Borne (Brussels, BELGIUM)
- 3. Renin-angiotensin-system blockers and their use during the Covid-19 pandemic**
G. Mancia (Milan, ITALY)

 SUPPORTED BY UNRESTRICTED EDUCATIONAL GRANT OF  PRODUCED BY
TERMEDIA PUBLISHING HOUSE 

Webinar 2



eshonline

MANAGEMENT OF HYPERTENSION DURING THE COVID-19 PANDEMIC AND BEYOND *Part. 2*

Moderator: A. Januszewicz (Warsaw, POLAND)

- 1. Comparison between 2018 European and 2020 ISH global guidelines for the management of hypertension**
R. Kreutz (Berlin, GERMANY)
- 2. Management of drug treatment and adherence in clinical practice**
M. Burnier (Lausanne, SWITZERLAND)
- 3. Perspectives for interventional treatment in hypertension**
K. Tsioufis (Athens, GREECE)

SUPPORTED BY UNRESTRICTED EDUCATIONAL GRANT OF

PRODUCED BY
TERMEDIA PUBLISHING HOUSE

SERVIER

TERMEDIA

10. ESH EDUCATIONAL ACTIVITIES

- b. Webinar 'Controversial issues of recent Guidelines' (E. Agabiti Rosei)
Educational Grant by Menarini

ESH WEBINARS 2021

Supported by Menarini Group



**European
Society of
Hypertension**



FORMAT

Menarini Group is going to support 2 webinars in 2021

**A
P
R
I
L

2
8**

CONTROVERSIAL AND MISSING ISSUES OF RECENT HYPERTENSION GUIDELINES – PART I

Chair : R. Kreutz - E. Agabiti Rosei

- **Out of office BP measurement and role of new devices** - *G. Mancia*
- **Old and new CV risk factors for the assessment of global risk** - *G. Grassi*
- **Essentials in the workup of secondary hypertension** - *A. Januszewicz*
- **Thresholds and targets of treatment** - *J. Redon*
- **Combination treatment** - *A. Coca*

(introduction 5 min., each presentation 15 min. including discussion, total duration 80 min)

**M
A
Y

2
6**

CONTROVERSIAL AND MISSING ISSUES OF RECENT HYPERTENSION GUIDELINES – PART II

Chair : G. Mancia - A. Januszewicz

- **Adherence to treatment** - *M. Burnier*
- **Covid-19 and antihypertensive treatment** - *R. Kreutz*
- **Treatment of concomitant cardiometabolic risk factors and of HMOD** - *E. Agabiti Rosei*
- **Treatment with antiplatelets and anticoagulants** - *A. Manolis*
- **Device based treatment** - *C. Tsioufis*

(introduction 5 min., each presentation 15 min. including discussion, total duration 80 min)

WHAT THE PARTICIPANT NEEDS TO INTERACT



PC, Mac or smartphone
with internet connection



Headphones or speakers



Microphone



Webcam

Thank you

10. ESH EDUCATIONAL ACTIVITIES

- c. Webinar series „Educational Imaging Program in Hypertension“
in cooperation with Siemens Healthcare Poland (A. Januszewicz)

13.00-17.00

BLUE HALL

Hands-on Workshop of the ESH Working Group on Hypertension and the Kidney

RENAL ULTRASOUND IN HYPERTENSION

Chairpersons: A. Persu (Brussels, BELGIUM), G. Wuerzner (Lausanne, SWITZERLAND)

13.00-13.10 Welcome address

A. Persu (Brussels, BELGIUM), G. Wuerzner (Lausanne, SWITZERLAND)

13.10-13.20 Technical basics of ultrasound and indications to perform a renal ultrasound in hypertensive patients

M. Pruijm (Lausanne, SWITZERLAND)

13.20-13.35 Normal anatomic findings and common abnormalities of the renal and urogenital tract (renal masses, nephrolithiasis, hydronephrosis)

M. Januszewicz (Warsaw, POLAND)

13.35-14.00 Renal duplex ultrasound: atherosclerotic renal artery stenosis / renal resistive indexes

B. Ponte (Geneve, SWITZERLAND)

14.00-14.15 Old and novel ultrasound applications in Fibromuscular Dysplasia

R.M. Bruno (Pisa, ITALY), A. Persu (Brussels, BELGIUM)

14.15-14.30 Beyond the kidney: aorta and adrenal glands

I. Petrucci (Pisa, ITALY)

14.30-14.40 Break

14.40-15.20 Practical examination of the kidney, aorta and adrenal glands by experts

M. Januszewicz (Warsaw, POLAND), I. Petrucci (Pisa, ITALY),
B. Ponte (Geneve, SWITZERLAND), M. Pruijm (Lausanne, SWITZERLAND)

15.20-16.50 Hands-on kidney ultrasound with healthy volunteers and supervision with experts (Practice)

M. Januszewicz (Warsaw, POLAND), I. Petrucci (Pisa, ITALY),
B. Ponte (Geneve, SWITZERLAND), M. Pruijm (Lausanne, SWITZERLAND)

16.50-17.00 General discussion with experts and participants



Hands-on Workshop

Attended by > 120
doctors

Interactive

Duration - 4 h



the global
hypertension
hub

JOINT MEETING **ESH-ISH** 2020 Glasgow

May 29 - June 1, 2020
Scottish Event Campus
Glasgow, United Kingdom
www.hypertension2020.org



European
Society of
Hypertension



International
Society of
Hypertension



British
Hypertension
Society

Hands-on Workshop of the ESH Working Group
on Hypertension and the Kidney

Session organized by
Alexandre Persu, Menno Pruijm,
Magda Januszewicz, Andrzej Januszewicz

SIEMENS
Healthineers

Warsaw, Poland

Offered delivery of Doppler ultrasound
machines for the session in Glasgow
and technical assistance



**European
Society of
Hypertension**

SIEMENS Healthineers Poland

will provide ESH with an educational grant (2021) to organize a series of webinars on radiological imaging techniques frequently used in hypertensive patients.

Preparation, recording, broadcasting and distribution on social media and on the ESH website

3 consecutive webinar programs focused on:

- Renal Doppler Ultrasound
- Computed Tomography
- Magnetic Resonance

“ESH-Siemens Educational Imaging Program”

- Under auspices of the ESH President and endorsed by the ESH Scientific Council
- Prepared by the following faculty members:
Alexandre Persu, Menno Pruijm, Magdalena Januszewicz, Spyridon Arampatzis, Belén Ponte, Andrzej Januszewicz, Aleksander Prejbisz and Piotr Dobrowolski



First webinar - February 11, 2021 - 5:00 pm - 7:20 pm (CET)


Welcome and Introduction by Reinhold Kreutz, President of ESH

Lectures

- Technical basics of renal ultrasound and normal findings
Spyridon Arampatzis , Bern, Switzerland (15 min)
- Common abnormalities of the urogenital tract (renal masses, nephrolithiasis, hydronephrosis)
Menno Pruijm, Lausanne, Switzerland (10 min)
- Renal duplex ultrasound: atherosclerotic renal artery stenosis and fibromuscular dysplasia:
Belen Ponte, Geneva, Switzerland (20 min)

Live part (90 min)

Doppler ultrasound examinations in patients with secondary hypertension in the Siemens Healthineers|Poland studio located in Warsaw, Poland.



Magda Januszewicz

Chairs and moderators



Alexandre Persu



Menno Pruijm



Andrzej Januszewicz



**European
Society of
Hypertension**

Alexandre Persu, Menno Pruijm, Andrzej Januszewicz and Mandy Elgner directly communicated with centers and invited participants

70 participants mostly hypertension specialists from European hypertension, cardiology and nephrology centers

Interactive character of the webinar to allow participants to ask questions online to Magda Januszewicz and to the chairs during examinations





Live Session on basics of renal ultrasound
in hypertensive patients

April 14, 2021

10. ESH EDUCATIONAL ACTIVITIES

- d. ESH participation in meetings and cooperation with other societies
 - 1. ESC: Joint Session at ESH-ISH at ESC Virtual Annual Meeting in April 2021 (T. Kahan)
 - 2. ESC: Joint Session at ESC Virtual Congress in August 2021 (T. Kahan)

10d. ESH EDUCATIONAL ACTIVITIES

Participation in meetings and cooperation
with other societies

(Thomas Kahan)

Planned Joint Session with ESC Council on Hypertension
at ESH-ISH Virtual Annual Meeting
April 12, 2021, 11AM-12PM

On the cross roads between hypertension and cardiology

Patterns of acute and protracted cardiac injury in covid-19

Giovanni de Simone, Napels, Italy

Treatment of hypertension in patients with HFpEF: current views and controversies

Alex Kasiakogias, London, UK

The role of blood pressure control in patients with atrial fibrillation on anticoagulant therapy

George Stergiou, Athens, Greece

Proposed Joint Sessions with ESC Council on Hypertension at ESC Virtual Annual Congress August 2021

- The 2021 Congress Spotlight is “Sudden Cardiac Death”
- Intra ESC scope: Represents an official contribution from ESC Associations/Councils and Working groups
- Two joint sessions have been submitted through Intrascopus 2021 by the ESC CHT
- Same proposals submitted by the ESH as request from other societies for joint sessions
- The CPC often revise proposed titles and participants
- It is open to propose further sessions; and joint sessions with several ESC Associations/Councils/ Working Groups may be relevant (, EHRA, EACVI, HFA, EACP, Stroke Council, and others)

Proposed Joint Sessions with ESC Council on Hypertension at ESC Virtual Annual Congress August 2021

Covid-19, hypertension, and antihypertensive medication

The role of the RAAS system in Covid-19

AH Jan Danser, the Netherlands

Acute clinical outcome of Covid-19 according to hypertension and medication

Isabella Sudano, Switzerland

Impact of Covid-19 lockdown on hypertension management

Philippe van de Borne, Belgium

The effect of Covid-19 pandemic on cardiovascular risk profiles in the population

Rosa Maria Bruno, France

Remarks: Proposed joint session with the ESH. Chairs Thomas Kahan, Sweden (ESC), and Reinhold Kreutz, Germany (ESH)

10. ESH EDUCATIONAL ACTIVITIES

- d. ESH participation in meetings and cooperation with other societies
 - 3. Russian Society of Hypertension Virtual Congress, March 2021 and others
- (R. Kreutz)

11. EXCELLENCE CENTRES

(T. Weber)

Excellence Centers




EXCELLENCE CENTRES APPLICATIONS

Requested on	Name	ESH ID	Email	Actions
January 29, 2021 14:58:14	Bruno Vogt	14909	bruno.vogt@insel.ch	Expand Approve Delete
January 24, 2021 13:55:53	Stella Stabouli, EHS ®	5883	sstaboul@auth.gr	Expand Approve Delete
January 22, 2021 23:55:16	Valentina Forni Ognà	17914	valentina.forniogna@eoc.ch	Expand Approve Delete
January 22, 2021 13:44:17	Andreas Schoenenberger	26284	andreas.schoenenberger@stgag.ch	Expand Approve Delete
December 31, 2020 21:06:19	Atul Pathak	38943	atul.pathak@chpg.mc	Expand Approve Delete

Blood Pressure Centers (Clinics)

APPROVED



12. ESH NEWSLETTERS

(G. Grassi)

Newsletters published in 2019

EFFECTS OF ANTIHYPERTENSIVE TREATMENT ON COGNITIVE DECLINE

Authors: Augusto Vicario, Antonio Coca, Dariusz Gasecki, Augusto Zaninelli, Dragan Lovic, Efstathios Manios, Dagmara Hering, Cristina Sierra, Pedro Cunha on behalf of the ESH WG on Hypertension and the Brain

HIGHLIGHTS OF THE 2016 EUROPEAN SOCIETY OF HYPERTENSION GUIDELINES FOR THE MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN AND ADOLESCENTS

Authors: Empar Lurbe, Elke Wühl, Stella Stabouli, Asle Hirth, Mieczyslaw Litwin, Denes Pall, Tomas Seeman on behalf of the Working Group of the 2016 European Society of Hypertension Guidelines for the Management of High Blood Pressure in Children and Adolescents

CARDIOVASCULAR RISK IN ETHNIC MINORITIES AND DISADVANTAGED POPULATIONS IN EUROPE

Authors: Pietro Amedeo Modesti, Gianfranco Parati, on behalf of the Working Group on “Hypertension and Cardiovascular Risk Assessment in Subjects Living in or Emigrating from Low Resource Settings”

CARDIOVASCULAR AND RENAL PROTECTION WITH NOVEL ANTIDIABETIC AGENTS BEYOND BLOOD GLUCOSE LOWERING IN TYPE 2 DIABETES. NEWSLETTER FROM THE EUROPEAN SOCIETY HYPERTENSION WORKING GROUP ON OBESITY, DIABETES AND THE HIGH RISK PATIENT

Authors: Vasilios Kotsis, Jens Jordan, Guido Grassi, Markus Schlaich, Peter M. Nilsson

Newsletters published in 2020

COVID-19 AND RAS BLOCKERS: A PHARMACOLOGY PERSPECTIVE

Author: A.H. Jan Danser

ATTENDED VS. UNATTENDED BLOOD PRESSURE – LEARNINGS BEYOND SPRINT

Authors: Sverre E. Kjeldsen, Guido Grassi, Reinhold Kreutz, Giuseppe Mancia

Newsletters planned to be published in 2021 so far:

NOCTURNAL HYPERTENSION

Author: Dr. Maria Tadic

NUTRACEUTICALS AND BP

Authors: Prof. Claudio Borghi, Prof. Arrigo Cicero

VITAMIN D AND HYPERTENSION

Author: Prof. Thomas Weber

FROM HYPERTENSION TO HEART FAILURE: PATHOPHYSIOLOGY, DIAGNOSTIC
APPROACH AND TREATMENT

Author: Prof. Athanasios Manolis

13. INTERACTION WITH NATIONAL SOCIETIES

(M. Dorobantu)

Open Discussion

Should we schedule a meeting with the Presidents of the National Societies during the ESH-ISH Virtual Annual Meeting?

14. ESH RELATIONSHIP WITH LATIN AMERICA

(A. Coca)

Relations with Latin America

ESH Association Program

Current Associated Societies:

1. Latin American Society of Hypertension (LASH)
2. Capítulo Mexicano de LASH
3. Hypertension Division of the Brazilian Society of Cardiology (DHA-BSC)
4. Sociedad Argentina de Hipertensión (SAHA)
5. Sociedad Venezolana de Hipertensión (SVHTA)
6. Sociedad Centroamericana y del Caribe de Hipertensión y Prevención Cardiovascular (SCCH)
7. Sociedad Dominicana de Hipertensión y Arteriosclerosis (SODOHAS)
8. **Inter American Society of Hypertension (IASH)**

Relations with Latin America

ESH Association Program

ASSOCIATION WITH THE EUROPEAN SOCIETY OF HYPERTENSION

This Agreement dated: January 14th, 2021

BETWEEN

The European Society
whose registered office
6301 Zug, Switzerland, a
in his capacity as Presid
herein referred to as the

AND

The Inter American S
registered office at 204
represented by Prof. Lu

Signed by **Professor Reinhold Kreutz**

President European Society of Hypertension

Date: January 14th, 2021

Signature:



Signed by **Professor Luis Alcocer**

President Inter American Society of Hypertension

Date: January 14th, 2021

Signature:



Relations with Latin America

ESH Association Program



This is to certify that the

*Inter American Society of Hypertension
(IASH)*

qualifies as an

ASSOCIATED SOCIETY

of the

EUROPEAN SOCIETY OF HYPERTENSION



Reinhold Kreutz
ESH President



Antonio Coca
*Executive Officer ESH Latin America
Relationships*

15. ESH SUMMER SCHOOL

(J. Brguljan)

Summer School 2021

Depending on the pandemic situation, we should decide by the end of March/beginning of April whether the Summer School can take place in presence as planned for 2020.

Should it take place, the applicants from 2020 will be present in Serbia.

Planned Date: 11.-16. September 2021

Planned Venue: Sremski Karlovci, Serbia

If the situation remains unpredictable, there are some ideas for a virtual realization of the event. In addition, we should allow the participants some benefits.

Summer School 2021 – ideas for virtual event

- Contact with all candidates and organizing discussion online about important publications on the field of hypertension with some of our council members
- Discussion about important study recently published and establishing network of candidates
- Ask Servier for additional funding for a dedicated live webinar

Possible benefits for applicants:

- Free access to ESH-ISH Virtual Congress
- Selection of new talents in hypertension from Summer School applicants. They are then given a presentation slot at the annual meeting and can report on their experiences at the Summer School.

16. ANY OTHER ISSUES

(A. Januszewicz)

World Hypertension Day - Motto

(R. Kreutz)



***Measure Your Blood Pressure,
Control It, Live Longer***

www.whleague.org

May 17, 2021
Save the Date!

17. DATES FOR FUTURE COUNCIL MEETINGS

(A. Januszewicz)

- a. Virtual Meeting on April 10, 2021
- b. Fall Meeting Oct/Nov 2021 (TBC)

18. CLOSURE OF THE MEETING

(R. Kreutz)

We wish you a nice weekend!

